Mark A. Socinski, MD, discussed how the understanding of lung cancer has evolved over time, as well as how its heterogeneity impacts treatment strategies.
Mark A. Socinski, MD, executive director at AdventHealth Cancer Institute, explained how the understanding of lung cancer has evolved in recent years, as well as how the heterogeneity of the disease impacts treatment decisions.
Transcript
Can you speak to the heterogeneity of lung cancer and why differentiation between subtypes is important?
Historically, if you go back 30 years or so ago, we divided lung cancer into 2 major groups: non–small cell and small cell. Non–small cell was a broad group of patients; we have now learned over the past decade or so that there are many subsets within the category of non–small cell lung cancer. These subsets are defined by either DNA mutations or fusions, as well as PD-L1 status. So, it is no longer true that one size fits all in terms of the treatment of lung cancer. You have to know the results from comprehensive genomic testing to see if the patient does have a specific mutation or a specific fusion in which there's an FDA-approved therapy. And the reason these targeted therapies—and we use the term targeted therapies because we think those DNA alterations and fusions and these sorts of things are our targets. These drugs are designed to inhibit the target, and we use the term targeted therapy.
You need to know that targeted therapies are much more highly effective than chemotherapy, and patients that have these DNA targets tend not to get the same benefit from immunotherapy. So, we want to get the right treatment to the right patient at the right time, and that really demands us knowing whether or not they have a target. The flip side of that is if you don't have a target, then PD-L1 status makes a difference. It makes a difference in the sense that it tells us how engaged the immune system might be, and it does predict for the option of using immunotherapy by itself without chemotherapy if there's very high PD-L1 expression.
We like to think that we're much more customized by delivering much more personalized treatment to patients based upon understanding that, again, one size doesn't fit all, and we need to know the comprehensive genomic information, the PD-L1 status, to say, "This is your diagnosis and this is the way that we should treat it initially."
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
AA Unlikely to Cause Anxiety, Depression but May Be Affected by Mental Illness
May 7th 2024A Mendelian randomization study using genetic analysis found that alopecia areata (AA) increases the risk of anxiety and depression, but not the other way around, providing unique evidence for a causal link while adding to existing evidence.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
AUA Session Highlights the General Urologist’s Role in Gender-Affirming Care
May 7th 2024During her session, Polina Reyblat, MD, Kaiser Permanente Los Angeles Medical Center, highlighted best practices urologists should incorporate to make transgender and gender-diverse patients comfortable during physical exams and avoid retraumatization.
Read More